Sildenafil in Treating Erectile Dysfunction in Patients With Prostate Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Prior treatment on RTOG-9910 for intermediate relapse-risk stage II or III prostate cancer as determined by any of the following combinations of factors:
• •* T1b-4, Gleason score 2-6, and prostate-specific antigen (PSA) greater than 10 ng/mL but no greater than 100 ng/mL
• •* T1b-4, Gleason score 7, and PSA less than 20 ng/mL
• •* T1b-1c, Gleason score 8-10, and PSA less than 20 ng/mL
• •Radiotherapy completed within the past 6 months to 5 years
• •Pretreatment (before enrollment on this study) erectile dysfunction as measured by International Index of Erectile Function Question #1
• •* Erectile dysfunction before starting prostate cancer therapy allowed
• •Patients without partners or without partners willing to participate allowed
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •Zubrod 0-2
• •Life expectancy
• •Not specified
• •Hematopoietic
• •Not specified
• •Hepatic
• •Not specified
• •Renal
• •Not specified
• •Cardiovascular
• •No myocardial infarction within the past year
• •Other
• •No other invasive cancer within the past 5 years except localized basal cell or squamous cell skin cancer (stage 0-II)
• •No anatomical genital abnormalities or concurrent conditions that would prohibit sexual intercourse or preclude study participation
• •No other major medical or psychiatric illness that would preclude study participation
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •Not specified
• •Endocrine therapy
• •More than 6 months since prior androgen suppression (e.g., leuprolide or goserelin), antiandrogen (e.g., bicalutamide, flutamide, or nilutamide), or estrogenic (e.g., diethylstilbestrol) agents
• •Radiotherapy
• •See Disease Characteristics
• •Surgery
• •No prior penile implant
• •No prior bilateral orchiectomy
• •Other
• •No concurrent sildenafil
• •No concurrent participation in another medical research study to treat prostate cancer
• •No concurrent organic nitrate or requirement for nitrates (e.g., nitroglycerin as needed)
• •No concurrent ketoconazole, itraconazole, or erythromycin
• •No concurrent use of mechanical (vacuum) devices or intracorporeal, intraurethral, topical, or oral agents for erectile dysfunction